drugset / Trial / NCT02024841
Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis
NaSingle-groupOpen-labelTreatment
Summary
Phase I study on the maximum tolerated dose (MTD) and the recommended dose (RD) of intraperitoneal docetaxel combined with intravenous cisplatin and oral TS-ONE in gastric cancer patients with peritoneal carcinomatosis
Timeline
- Start
- 2013-12
- Primary completion
- 2017-02
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 40 mg/m2 | Other |
| Subject | Docetaxel | Small molecule | 50 mg/m2 | Other |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Other |
| Subject | TS-ONE | Unknown | 40 mg | Oral |
| Subject | TS-ONE | Unknown | 60 mg | Oral |